Biosite® Inc. Web Site -- Products

By: Alere  09-12-2011

Better outcomes begin with better diagnosis

Diagnosis is the critical link in medicine today. Timely, accurate diagnosis can mean the difference between relief of symptoms and prolonged suffering, between early intervention and missed therapeutic opportunities, and, in the gravest instances, between life and death.

Finding better and faster ways to achieve accurate diagnosis can potentially improve patient management, lead to earlier therapeutic intervention and reduce the costs associated with indecision, benefiting both patients and healthcare providers.

Better diagnosis begins with Biosite®

Striving for sustained growth, Biosite has adopted a strategy that encompasses the diagnostic continuum from protein validation to patient care. Through combined expertise in diagnostic discovery and commercialization, Biosite is focused on developing novel diagnostics tests that are capable of immediately and accurately diagnosing and assessing critical conditions, which can take several hours or even days using conventional testing methods.

For years, Biosite customers around the globe have validated our approach to the science of diagnosis, and as a result, a company that once seemed radically at odds with the diagnostic industry’s norms is now a fixture in health care settings of every imaginable size and type. Today, in fact, Biosite technology is used in physician's office laboratories, more than 50% of all U.S. hospitals and in approximately 40 other countries by clinicians who share our belief that a better, more rapid diagnosis can lead to better outcomes.

Other products and services from Alere


Biosite® Inc. Web Site -- Cardiac Panel

Finally, technology that has caught up with your needs.Rapid, quantitative measurement of CK-MB, myoglobin, and troponin I to aid in the diagnosis of acute myocardial infarction. Rapid, actionable information to aid in the diagnosis of acute myocardial infarction. Enables triage decisions in under two hours when used with accelerated protocol 1. Simultaneous cardiac marker results from whole blood in approximately 15 minutes.


Biosite® Inc. Web Site -- D-Dimer Test

A rapid, quantitative immunoassay to aid in the assessment and evaluation of patients suspected of having disseminated intravascular coagulation and thromboembolic events including pulmonary embolism and deep vein thrombosis. Performed on the Triage Meters.


Biosite® Inc. Web Site -- Profiler Shortness of Breath

The Triage® Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment of patients with acute coronary syndromes. Troponin I, CK-MB, myoglobin, BNP and D-dimer each provide unique clinical information, and the panel approach maximizes the strengths of each marker.


Biosite® Inc. Web Site -- TOX Drug Screen -- TOX Drug Screen

According to the National Academy of Clinical Biochemistry, Laboratory Medicine Practice Guidelines, stat toxicology assays required to support an ED should have a turnaround time of one hour or less. The Value of Point-of-Care Drug Testing Nearly every day patients are treated in emergency departments across the country for complications due to drug overdose.


Biosite® Inc. Web Site -- Triage System

An immunoassay for use as an aid in the diagnosis of acute myocardial infarction, the diagnosis and assessment of severity of congestive heart failure, and the risk stratification of patients with acute coronary syndromes and congestive heart failure. An immunoassay for the quantitative determination of CK-MB, myoglobin, and troponin I in whole blood or plasma, as an aid in the diagnosis of acute myocardial infarction.


Biosite® Inc. Web Site -- Triage® BNP Test

The Triage BNP Test is intended for use with the Triage Meters for the rapid in vitro quantitative measurement of B-Type Natriuretic Peptide in human whole-blood or plasma specimens using EDTA as the anticoagulant. 98 percent diagnostic accuracy in initial studies versus all other clinical findings in patients with or without disease history3.